ARTICLE | Clinical News

Kynamro mipomersen: Phase III data

April 23, 2012 7:00 AM UTC

An open-label, international Phase III extension study in 53 evaluable patients with hypercholesterolemia showed that once-weekly subcutaneous injections of 200 mg Kynamro for 2 years maintained a significant 28% reduction in mean LDL-C from baseline to week 104 (p<0.001). At week 104, Kynamro also significantly reduced non-HDL-C, APOB and LPA from baseline by 27%, 31% and 14%, respectively, while significantly increasing HDL-C by 10% from baseline (p<=0.01 for all). The trial enrolled patients with homozygous familial hypercholesterolemia (hoFH), severe hypercholesterolemia or heterozygous familial hypercholesterolemia (heFH) who were previously enrolled in 1 of 3 six-month Phase III trials of Kynamro. Data were presented at the International Symposium on Atherosclerosis in Sydney. ...